VANCOUVER and MENLO PARK,Calif., Dec. 2, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and "DelMar Pharma"), a clinical stage drug development company focused on the development and commercialization of a new chemotherapy for the treatment of refractory glioblastoma multiforme (GBM), the most common and deadly form of human brain cancer, announced that it will begin trading today on the OTCQX® marketplace.
U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com
"We are proud to welcome DelMar Pharmaceuticals to the OTCQX marketplace," said R. Cromwell Coulson, president and CEO of OTC Markets Group. "DelMar Pharmaceuticals joins the growing group of U.S. and global companies that are choosing to trade on OTCQX to provide their investors with transparent trading and convenient access to their news and financial disclosure. We congratulate DelMar Pharmaceuticals' management team on this achievement and wish the company continued success."
DelMar Pharmaceuticals president and CEO Jeffrey Bacha commented, "DelMar is pleased to upgrade from OTCQB today and join the many top tier companies trading on the prestigious OTCQX marketplace. This is an important step forward for our company as we advance our drug development programs toward commercialization and seek to deliver long-term shareholder value."
About The OTCQX Marketplace
The OTCQX marketplace is designed for investor-focused companies that meet high financial standards, are current in their disclosure and are sponsored by a third party advisor. The companies found on OTCQX are distinguished by the excellence of their operations and diligence with which they convey their qualifications. OTCQX includes over 350 world-class companies (ranging from global blue chips to U.S. high growth) with a combined total market capitalization of $1.7 trillion and $29.5 billion in annual trading volume.
About DelMar Pharmaceuticals, Inc.
DelMar Pharmaceuticals, Inc. was founded to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing or have become intolerable to modern targeted or biologic treatments. The Company's lead drug in development, VAL-083, is currently undergoing clinical trials in the U.S. as a potential treatment for refractory glioblastoma multiforme. VAL-083 has been extensively studied by U.S. National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia (CML) and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action that could provide improved treatment options for patients.
Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.
SOURCE DelMar Pharmaceuticals, Inc.